You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Colorcon
Medtronic
Moodys
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,687,466

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,687,466
Title:Use of dianhydrogalactitol and analogs and derivatives thereof to treat glioblastoma multiforme
Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N.sup.7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
Inventor(s): Bacha; Jeffrey A. (Vancouver, CA), Brown; Dennis (Menlo Park, CA), Dunn; Sandra (Vancouver, CA), Steino; Anne (Vancouver, CA)
Assignee: DELMAR PHARMACEUTICALS, INC. (Vancouver, CA)
Application Number:14/245,738
Patent Claims:see list of patent claims

Details for Patent 9,687,466

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial DELMAR PHARMACEUTICALS, INC. (Vancouver, CA) 2032-01-20 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial DELMAR PHARMACEUTICALS, INC. (Vancouver, CA) 2032-01-20 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial DELMAR PHARMACEUTICALS, INC. (Vancouver, CA) 2032-01-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Moodys
Express Scripts
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.